Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity

ACS Chemical Neuroscience

Volumn 6, Issue 5, 2015, Pages 790-799

  Lohr, Kelly M ^a   Stout, Kristen A ^a   Dunn, Amy R ^a   Wang, Minzheng ^a   Salahpour, Ali ^c   Guillot, Thomas S ^a   Miller, Gary W ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

dopamine; inflammation; Methamphetamine; neurodegeneration; vesicle; VMAT2

Indexed keywords

DOPAMINE TRANSPORTER; GLIAL FIBRILLARY ACIDIC PROTEIN; METHAMPHETAMINE; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2; CENTRAL STIMULANT AGENT; SLC18A2 PROTEIN, MOUSE; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; CORE TEMPERATURE; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC SYSTEM; GLIOSIS; HYPERTHERMIA; IN VIVO STUDY; INFLAMMATION; LOCOMOTION; MACROGLIA; MALE; METHAMPHETAMINE TOXICITY; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REWARD; SYNAPSE; WILD TYPE MOUSE; ANIMAL; C57BL MOUSE; IMMUNOHISTOCHEMISTRY; METABOLISM; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALIA; MUS;

ANIMALS; BLOTTING, WESTERN; CENTRAL NERVOUS SYSTEM STIMULANTS; IMMUNOHISTOCHEMISTRY; MALE; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84930196022     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/acschemneuro.5b00010     Document Type: Article

References (80)

1. Ricaurte, G. A., Guillery, R. W., Seiden, L. S., Schuster, C. R., and Moore, R. Y. (1982) Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain Brain Res. 235, 93-103
2. LaVoie, M. J., Card, J. P., and Hastings, T. G. (2004) Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity Exp. Neurol. 187, 47-57
3. Kuhn, D. M., Francescutti-Verbeem, D. M., and Thomas, D. M. (2006) Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage Ann. N. Y. Acad. Sci. 1074, 31-41
4. Cubells, J. F., Rayport, S., Rajendran, G., and Sulzer, D. (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress J. Neurosci. 14, 2260-2271
5. Ricaurte, G. A., Seiden, L. S., and Schuster, C. R. (1984) Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers Brain Res. 303, 359-364
6. Sulzer, D. 1995, Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport J. Neurosci. 15, 4102-4108
7. Peter, D., Jimenez, J., Liu, Y., Kim, J., and Edwards, R. H. (1994) The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors J. Biol. Chem. 269, 7231-7237
8. Torres, B. and Ruoho, A. E. (2014) N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux Neuroscience 259, 194-202
9. LaVoie, M. J. and Hastings, T. G. (1999) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: Evidence against a role for extracellular dopamine J. Neurosci. 19, 1484-1491
10. Lotharius, J. and O'Malley, K. L. (2001) Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity Ann. Neurol. 49, 79-89
11. Sulzer, D. and Zecca, L. (1999) Intraneuronal dopamine-quinone synthesis: A review Neurotox Res. 1, 181-195
12. Larsen, K. E., Fon, E. A., Hastings, T. G., Edwards, R. H., and Sulzer, D. (2002) Methamphetamine-Induced Degeneration of Dopaminergic Neurons Involves Autophagy and Upregulation of Dopamine Synthesis J. Neurosci. 22, 8951-8960
13. Osamu, S., Hideki, H., Minoru, A., Masakazu, O., and Yoshinao, K. (1980) Inhibition of monoamine oxidase by d-methamphetamine Biochem. Pharmacol. 29, 2071-2073
14. Yuan, J. 2010, Dopamine is not essential for the development of methamphetamine-induced neurotoxicity J. Neurochem. 114, 1135-1142
15. Yamamoto, B. K. and Zhu, W. (1998) The effects of methamphetamine on the production of free radicals and oxidative stress J. Pharmacol. Exp. Ther. 287, 107-114
16. Callahan, B. T., Cord, B. J., Yuan, J., McCann, U. D., and Ricaurte, G. A. (2001) Inhibitors of Na+/H+ and Na+/Ca2+ exchange potentiate methamphetamine-induced dopamine neurotoxicity: possible role of ionic dysregulation in methamphetamine neurotoxicity J. Neurochem. 77, 1348-1362
17. Brown, J. M. and Yamamoto, B. K. (2003) Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress Pharmacol. Ther. 99, 45-53
18. O'Callaghan, J. P. and Miller, D. B. (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse J. Pharmacol. Exp. Ther. 270, 741-751
19. Hess, A., Desiderio, C., and McAuliffe, W. G. (1990) Acute neuropathological changes in the caudate nucleus caused by MPTP and methamphetamine: immunohistochemical studies J. Neurocytol. 19, 338-342
20. Thomas, D. M., Walker, P. D., Benjamins, J. A., Geddes, T. J., and Kuhn, D. M. (2004) Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation J. Pharmacol. Exp. Ther. 311, 1-7
21. Guilarte, T. R., Nihei, M. K., McGlothan, J. L., and Howard, A. S. (2003) Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity Neuroscience 122, 499-513
22. Erickson, J. D., Eiden, L. E., and Hoffman, B. J. (1992) Expression cloning of a reserpine-sensitive vesicular monoamine transporter Proc. Natl. Acad. Sci. U. S. A. 89, 10993-10997
23. Erickson, J. D. and Eiden, L. E. (1993) Functional identification and molecular cloning of a human brain vesicle monoamine transporter J. Neurochem. 61, 2314-2317
24. Eiden, L. E. and Weihe, E. (2011) VMAT2: A dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse Ann. N. Y. Acad. Sci. 1216, 86-98
25. Liu, Y. 1992, A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter Cell 70, 539-51
26. Goldstein, D. S. 2013, Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease J. Neurochem. 126, 591-603
27. Alter, S. P., Lenzi, G. M., Bernstein, A. I., and Miller, G. W. (2013) Vesicular integrity in Parkinson's disease Curr. Neurol. Neurosci. Rep. 13, 362
28. Wang, Y. M. 1997, Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine Neuron 19, 1285-1296
29. Takahashi, N. 1997, VMAT2 knockout mice: Heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity Proc. Natl. Acad. Sci. U. S. A. 94, 9938-9943
30. Fon, E. A. 1997, Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action Neuron 19, 1271-1283
31. Caudle, W. M. 2007, Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration J. Neurosci. 27, 8138-8148
32. Taylor, T. N., Alter, S. P., Wang, M., Goldstein, D. S., and Miller, G. W. (2014) Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus Neuropharmacology 76, 97-105
33. Rilstone, J. J., Alkhater, R. A., and Minassian, B. A. (2013) Brain dopamine-serotonin vesicular transport disease and its treatment New Engl. J. Med. 543-550
34. Pifl, C. 2014, Is Parkinson's Disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum J. Neurosci. 34, 8210-8218
35. Lohr, K. M. 2014, Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo Proc. Natl. Acad. Sci. U. S. A. 111, 9977-9982
36. Ugarte, Y., Rau, K. S., Riddle, E. L., Hanson, G. R., and Fleckenstein, A. E. (2003) Methamphetamine rapidly decreases mouse vesicular dopamine uptake: Role of hyperthermia and dopamine D2 receptors Eur. J. Pharmacol. 472, 165-171
37. Guillot, T. S. 2008, Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis J. Neurochem. 106, 2205-2217
38. Fumagalli, F. 1999, Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice J. Neurosci. 19, 2424-2431
39. Granado, N. 2010, Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration: Early loss of TH in striosomes after methamphetamine Neurotoxic. Res. 18, 48-58
40. Miller, D. B. and O'Callaghan, J. P. (1994) Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J. mouse J. Pharmacol. Exp. Ther. 270, 752-760
41. Cunningham, C. L. and Noble, D. (1992) Methamphetamine-induced conditioned place preference or aversion depending on dose and presence of drug Ann. N. Y. Acad. Sci. 654, 431-433
42. Guillot, T. S. and Miller, G. W. (2009) Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons Mol. Neurobiol. 2, 149-170
43. Caudle, W. M., Colebrooke, R. E., Emson, P. C., and Miller, G. W. (2008) Altered vesicular dopamine storage in Parkinson's disease: a premature demise Trends Neurosci 31, 303-308
44. Gainetdinov, R. R. 1998, Increased MPTP Neurotoxicity in Vesicular Monoamine Transporter 2 Heterozygote Knockout Mice J. Neurochem. 70, 1973-1978
45. Wang, Y. M. 1997, Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine Neuron 19, 1285-1296
46. Medina, L., Figueredo-Cardenas, G., and Reiner, A. (1996) Differential abundance of superoxide dismutase in interneurons versus projection neurons and in matrix versus striosome neurons in monkey striatum Brain Res. 708, 59-70
47. Breuer, O., Lawhorn, C., Miller, T., Smith, D. M., and Brown, L. L. (2005) Functional architecture of the mammalian striatum: Mouse vascular and striosome organization and their anatomic relationships Neurosci. Lett. 385, 198-203
48. Fumagalli, F., Gainetdinov, R. R., Valenzano, K. J., and Caron, M. G. (1998) Role of dopamine transporter in methamphetamine-induced neurotoxicity: Evidence from mice lacking the transporter J. Neurosci. 18, 4861-4869
49. Bowyer, J. F. 1992, The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum J. Pharmacol. Exp. Ther. 260, 817-824
50. Bowyer, J. F. 1994, Further studies of the role of hyperthermia in methamphetamine neurotoxicity J. Pharmacol. Exp. Ther. 268, 1571-1580
51. Albers, D. S. and Sonsalla, P. K. (1995) Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents J. Pharmacol. Exp. Ther. 275, 1104-1114
52. Lessin, A. W. and Parkes, M. W. (1957) The hypothermic and sedative action of reserpine in the mouse J. Pharm. Pharmacol. 9, 657-662
53. Thiriet, N. 2011, Environmental enrichment does not reduce the rewarding and neurotoxic effects of methamphetamine Neurotoxic. Res. 19, 172-182
54. Shimosato, K. and Ohkuma, S. (2000) Simultaneous Monitoring of Conditioned Place Preference and Locomotor Sensitization Following Repeated Administration of Cocaine and Methamphetamine Pharmacol., Biochem. Behav. 66, 285-292
55. Sulzer, D. and Rayport, S. (1990) Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action Neuron 5, 797-808
56. Sulzer, D. 1992, Weak base model of amphetamine action Ann. N. Y. Acad. Sci. 654, 525-528
57. Whitehead, R. E., Ferrer, J. V., Javitch, J. A., and Justice, J. B. (2001) Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter J. Neurochem. 76, 1242-1251
58. Park, S. U., Ferrer, J. V., Javitch, J. A., and Kuhn, D. M. (2002) Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: Potential mechanism of neurotoxicity in dopamine neurons J. Neurosci. 22, 4399-4405
59. Kuhn, D. M., Arthur, R. E., Thomas, D. M., and Elferink, L. A. (2001) Tyrosine Hydroxylase Is Inactivated by Catechol-Quinones and Converted to a Redox-Cycling Quinoprotein J. Neurochem. 73, 1309-1317
60. Eisenhofer, G., Kopin, I. J., and Goldstein, D. S. (2004) Catecholamine metabolism: a contemporary view with implications for physiology and medicine Pharmacol. Rev. 56, 331-349
61. Burke, W. J., Li, S. W., Williams, E. A., Nonneman, R., and Zahm, D. S. (2003) 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: Implications for Parkinson's disease pathogenesis Brain Res. 989, 205-213
62. Burke, W. J. 2008, Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine Acta Neuropathol. 115, 193-203
63. Anderson, D. G., Mariappan, S. V. S., Buettner, G. R., and Doorn, J. A. (2011) Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone J. Biol. Chem. 286, 26978-26986
64. Vergo, S., Johansen, J. L., Leist, M., and Lotharius, J. (2007) Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels Brain Res. 1185, 18-32
65. Guillot, T. S. 2008, PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity Neuropeptides 42, 423-434
66. Mosharov, E. V., Gong, L.-W., Khanna, B., Sulzer, D., and Lindau, M. (2003) Intracellular patch electrochemistry: regulation of cytosolic catecholamines in chromaffin cells J. Neurosci. 23, 5835-5845
67. Mosharov, E. V. 2009, Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons Neuron 62, 218-229
68. Mosharov, E. V. 2006, Alpha-synuclein overexpression increases cytosolic catecholamine concentration J. Neurosci. 26, 9304-9311
69. Bolam, J. P. and Pissadaki, E. K. (2012) Living on the edge with too many mouths to feed: why dopamine neurons die Mov. Disord. 27, 1478-1483
70. Burrows, K. B., Gudelsky, G., and Yamamoto, B. K. (2000) Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration Eur. J. Pharmacol. 398, 11-18
71. Schinder, A. F., Olson, E. C., Spitzer, N. C., and Montal, M. (1996) Mitochondrial dysfunction is a primary event in glutamate neurotoxicity J. Neurosci. 16, 6125-6133
72. Dwoskin, L. P. and Crooks, P. A. (2002) A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse Biochem. Pharmacol. 63, 89-98
73. Nickell, J. R. 2010, Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2 J. Pharmacol. Exp. Ther. 332, 612-621
74. Miller, D. K. 2001, Lobeline Inhibits the Neurochemical and Behavioral Effects of Amphetamine J. Pharmacol. Exp. Ther. 296, 1023-1034
75. Taylor, T. N. 2009, Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity J. Neurosci. 29, 8103-8113
76. Freis, E. D. (1954) Mental depression in hypertensive patients treated for long periods with large doses of reserpine New Engl. J. Med. 251, 1006-1008
77. Pettibone, D. J., Totaro, J. A., and Pflueger, A. B. (1984) Tetrabenazine-induced depletion of brain monoamines: Characterization and interaction with selected antidepressants Eur. J. Pharmacol. 102, 425-430
78. Sulzer, D. (2007) Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease Trends Neurosci. 30, 244-250
79. Curtin, K. (2015) Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: A population-based assessment Drug Alcohol Depend. 146, 30-38
80. Callaghan, R. C., Cunningham, J. K., Sykes, J., and Kish, S. J. (2012) Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs Drug Alcohol Depend. 120, 35-40